Tyra Biosciences, Inc. (NASDAQ:TYRA – Get Free Report) COO Daniel Bensen sold 9,587 shares of Tyra Biosciences stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $18.09, for a total transaction of $173,428.83. Following the completion of the sale, the chief operating officer now owns 452,981 shares of the company’s stock, valued at $8,194,426.29. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
Tyra Biosciences Price Performance
Shares of TYRA stock opened at $18.42 on Monday. Tyra Biosciences, Inc. has a twelve month low of $9.70 and a twelve month high of $19.74. The company’s 50-day moving average price is $13.79 and its 200-day moving average price is $13.70.
Analyst Ratings Changes
TYRA has been the topic of a number of recent research reports. Bank of America lowered Tyra Biosciences from a “buy” rating to a “neutral” rating and dropped their target price for the company from $25.00 to $15.00 in a research report on Friday, December 15th. Wedbush reiterated an “outperform” rating and issued a $27.00 target price on shares of Tyra Biosciences in a research note on Friday, December 29th. Finally, HC Wainwright restated a “buy” rating and set a $19.00 price objective on shares of Tyra Biosciences in a research report on Tuesday, December 26th.
Institutional Trading of Tyra Biosciences
Several hedge funds have recently made changes to their positions in TYRA. UBS Group AG increased its position in shares of Tyra Biosciences by 3,841.8% during the 4th quarter. UBS Group AG now owns 3,587 shares of the company’s stock worth $27,000 after purchasing an additional 3,496 shares during the last quarter. Barclays PLC raised its stake in shares of Tyra Biosciences by 544.1% in the fourth quarter. Barclays PLC now owns 3,581 shares of the company’s stock valued at $27,000 after acquiring an additional 3,025 shares in the last quarter. Simplex Trading LLC boosted its stake in shares of Tyra Biosciences by 198.1% in the 3rd quarter. Simplex Trading LLC now owns 2,009 shares of the company’s stock valued at $27,000 after buying an additional 1,335 shares during the period. Federated Hermes Inc. lifted its stake in Tyra Biosciences by 1,244.2% in the fourth quarter. Federated Hermes Inc. now owns 2,070 shares of the company’s stock worth $29,000 after acquiring an additional 1,916 shares during the last quarter. Finally, Allspring Global Investments Holdings LLC purchased a new stake in shares of Tyra Biosciences during the 2nd quarter worth $39,000. Hedge funds and other institutional investors own 84.14% of the company’s stock.
About Tyra Biosciences
Tyra Biosciences, Inc, a clinical-stage biotechnology company, focuses on developing next-generation precision medicines for fibroblast growth factor receptor (FGFR) biology. The company offers SNÅP, an in-house precision medicine platform which precise drug design through iterative molecular snapshots to predict genetic alterations for developing oncology and genetically defined condition therapies.
- Five stocks we like better than Tyra Biosciences
- Earnings Per Share Calculator: How to Calculate EPS
- MarketBeat Week in Review – 2/5 – 2/9
- EV Stocks and How to Profit from Them
- Cloudflare results spark analysts reset: 25% upside ahead
- With Risk Tolerance, One Size Does Not Fit All
- Beyond Nvidia: The hidden stars with 200% earnings growth
Receive News & Ratings for Tyra Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tyra Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.